Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_assertion type Assertion NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_head.
- NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_assertion description "[The combination of IFN-gamma and CaM antagonists, including tamoxifen, may be a potential therapeutic modality for cholangiocarcinoma and possibly other malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_provenance.
- NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_assertion evidence source_evidence_literature NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_provenance.
- NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_assertion SIO_000772 14578204 NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_provenance.
- NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_assertion wasDerivedFrom befree-20150227 NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_provenance.
- NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_assertion wasGeneratedBy ECO_0000203 NP278711.RAwEa7hC-ZKYcyrrbR8pQHtH6Srt97Q8vwPA9UVeHy3ks130_provenance.